Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
Acta Haematologica|July 20, 2025
Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and CardiologistsTalha Munir, Eglė Čiburienė, Vasko Graklanov, et al.
Health Technology Assessment (Winchester, England)|June 20, 2017
Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trialDena R Howard, Talha Munir, Lucy McParland, et al.
Trials|August 24, 2017
Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trialLaura Collett, Dena R Howard, Talha Munir, et al.
Therapeutic Advances in Hematology|June 5, 2023
Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemiaWojciech Jurczak, Nagah Elmusharaf, Christopher P Fox, et al.
American Journal of Hematology|February 13, 2024
Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuriaMorag Griffin, Richard Kelly, Isabelle Brindel, et al.
British Journal of Haematology|June 17, 2026
Outcome of treatment with trametinib in adults with histiocytic neoplasms in the United KingdomRodothea Amerikanou, Talha Munir, Kristian Bowles, et al.
Leukemia & Lymphoma|January 11, 2022
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studiesJan A Burger, Tadeusz Robak, Fatih Demirkan, et al.
American Journal of Hematology|April 21, 2020
Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumabFraser L Macrae, Barnaby Peacock-Young, Polly Bowman, et al.
Hemasphere|July 15, 2026
Switching between complement inhibitors in paroxysmal nocturnal hemoglobinuria: Analysis of strategy, efficacy, and safetyMorag Griffin, Bruno Fattizzo, Jong Wook Lee, et al.
European Journal of Haematology|June 1, 2021
The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK's population-based haematological malignancy research network 2004-2018Stephen J Richards, Daniel Painter, Anita J Dickinson, et al.
Pageof 7